ReviewInvestigational new drugs2014
Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature.
Review in Investigational new drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.Journal of translational medicine · 2020Trial
- Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy.The Prostate · 2025Article
- C-C Chemokine Receptor 7 in Cancer.Cells · 2022Review
- PhosphodiesteraseInternational journal of molecular sciences · 2020Article
- Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.Nature communications · 2018Article
- The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.Oncotarget · 2017Article
- Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach.Frontiers in oncology · 2017Review
- Immune Infiltration and Prostate Cancer.Frontiers in oncology · 2015Review
- A primer on tumour immunology and prostate cancer immunotherapy.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A role for CD20 antibodies in treating prostate cancer has not yet been established. We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.